Published in Vaccine on June 30, 2004
Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun (2006) 1.92
Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun (2006) 1.59
Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun (2008) 1.18
Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium. Infect Immun (2005) 0.92
Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine (2007) 0.86
Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation. Infect Immun (2006) 0.83
Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice. Clin Vaccine Immunol (2009) 0.82
A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen. FEMS Immunol Med Microbiol (2007) 0.81
Developing live vaccines against plague. J Infect Dev Ctries (2011) 0.81
Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization. Cell Mol Immunol (2011) 0.79
Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques. Hum Vaccin Immunother (2013) 0.78
A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection. Infect Immun (2014) 0.78
Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague. Vaccine (2015) 0.76
Plague Vaccine Development: Current Research and Future Trends. Front Immunol (2016) 0.75
Comparison of virulence between the Yersinia pestis Microtus 201, an avirulent strain to humans, and the vaccine strain EV in rhesus macaques, Macaca mulatta. Hum Vaccin Immunother (2014) 0.75
Tularemia. Clin Microbiol Rev (2002) 8.51
Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A (2004) 7.30
The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet (2005) 6.22
Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol (2004) 5.38
Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J Clin Microbiol (2003) 3.08
Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringens. Genome Res (2006) 2.84
Absence of Yersinia pestis-specific DNA in human teeth from five European excavations of putative plague victims. Microbiology (2004) 2.75
Application of DNA microarrays to study the evolutionary genomics of Yersinia pestis and Yersinia pseudotuberculosis. Genome Res (2003) 2.51
Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology (2004) 2.28
ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun (2004) 2.15
A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A (2009) 2.10
Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics (2007) 1.85
Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol (2004) 1.82
From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics (2007) 1.68
A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence. PLoS Pathog (2010) 1.65
Direct repeat-mediated deletion of a type IV pilin gene results in major virulence attenuation of Francisella tularensis. Mol Microbiol (2006) 1.65
A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun (2002) 1.60
Variation in Salmonella enterica serovar typhi IncHI1 plasmids during the global spread of resistant typhoid fever. Antimicrob Agents Chemother (2008) 1.58
Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J Infect Dis (2005) 1.56
Clostridium perfringens epsilon-toxin shows structural similarity to the pore-forming toxin aerolysin. Nat Struct Mol Biol (2004) 1.55
Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J Med Microbiol (2003) 1.48
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology. Chem Biol (2013) 1.45
The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect Immun (2006) 1.42
Rethinking our understanding of the pathogenesis of necrotic enteritis in chickens. Trends Microbiol (2008) 1.39
Discrimination of human pathogenic subspecies of Francisella tularensis by using restriction fragment length polymorphism. J Clin Microbiol (2003) 1.38
Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol (2002) 1.37
A type IV pilin, PilA, Contributes To Adherence of Burkholderia pseudomallei and virulence in vivo. Infect Immun (2005) 1.34
Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun (2002) 1.33
Genotyping and phenotyping of beta2-toxigenic Clostridium perfringens fecal isolates associated with gastrointestinal diseases in piglets. J Clin Microbiol (2003) 1.32
Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis (2012) 1.28
A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science (2011) 1.27
Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology (2009) 1.23
Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun (2003) 1.23
Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev (2002) 1.22
Francisella tularensis vaccines. FEMS Immunol Med Microbiol (2007) 1.19
Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiol (2011) 1.19
Structural characterization of lipo-oligosaccharide (LOS) from Yersinia pestis: regulation of LOS structure by the PhoPQ system. Mol Microbiol (2002) 1.15
Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun (2007) 1.15
Vaccination strategies for Francisella tularensis. Adv Drug Deliv Rev (2005) 1.15
The ABC transporter protein OppA provides protection against experimental Yersinia pestis infection. Infect Immun (2006) 1.14
Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Vaccine (2005) 1.14
Insect infection model for Campylobacter jejuni reveals that O-methyl phosphoramidate has insecticidal activity. J Infect Dis (2010) 1.13
Characterization and deposition of respirable large- and small-particle bioaerosols. Appl Environ Microbiol (2008) 1.13
Interactions of the type III secretion pathway proteins LcrV and LcrG from Yersinia pestis are mediated by coiled-coil domains. J Biol Chem (2002) 1.12
Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. J Bacteriol (2006) 1.11
Development of vaccines against burkholderia pseudomallei. Front Microbiol (2011) 1.10
Genome sequencing shows that European isolates of Francisella tularensis subspecies tularensis are almost identical to US laboratory strain Schu S4. PLoS One (2007) 1.09
Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology (2005) 1.08
Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun (2006) 1.08
Experimental aerogenic Burkholderia mallei (glanders) infection in the BALB/c mouse. J Med Microbiol (2003) 1.07
Characterization of the Burkholderia pseudomallei K96243 capsular polysaccharide I coding region. Infect Immun (2012) 1.07
Immunization with the C-Domain of alpha -Toxin prevents lethal infection, localizes tissue injury, and promotes host response to challenge with Clostridium perfringens. J Infect Dis (2004) 1.06
Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine (2003) 1.05
Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl Trop Dis (2009) 1.05
Clostridium absonum alpha-toxin: new insights into clostridial phospholipase C substrate binding and specificity. J Mol Biol (2003) 1.05
Recombinant Bacillus subtilis expressing the Clostridium perfringens alpha toxoid is a candidate orally delivered vaccine against necrotic enteritis. Infect Immun (2008) 1.05
Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis. Am J Pathol (2011) 1.05
DNA vaccines: improving expression of antigens. Genet Vaccines Ther (2003) 1.04
Galleria mellonella as an infection model for Campylobacter jejuni virulence. J Med Microbiol (2011) 1.04
Molecular basis of toxicity of Clostridium perfringens epsilon toxin. FEBS J (2011) 1.02
The identification of surface proteins of Burkholderia pseudomallei. Vaccine (2006) 1.02
CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res (2005) 1.02
Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine (2009) 1.02
Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun (2006) 1.02
Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine (2010) 1.01
Progress toward development of vaccines against melioidosis: A review. Clin Ther (2010) 1.01
A bacterial process for selenium nanosphere assembly. Proc Natl Acad Sci U S A (2011) 1.01
The use of live attenuated bacteria as a delivery system for heterologous antigens. J Drug Target (2003) 1.01
Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine (2006) 1.00
A dam mutant of Yersinia pestis is attenuated and induces protection against plague. FEMS Microbiol Lett (2005) 1.00
ATP-binding cassette systems in Burkholderia pseudomallei and Burkholderia mallei. BMC Genomics (2007) 1.00
Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei. Infect Immun (2006) 0.99
Neutrophils are important in early control of lung infection by Yersinia pestis. Microbes Infect (2010) 0.99
Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect Immun (2003) 0.98
Molecular architecture and functional analysis of NetB, a pore-forming toxin from Clostridium perfringens. J Biol Chem (2012) 0.97
Age influences resistance of Caenorhabditis elegans to killing by pathogenic bacteria. FEMS Microbiol Lett (2004) 0.97
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun (2006) 0.97
A 55 kDa hypothetical membrane protein is an iron-regulated virulence factor of Francisella tularensis subsp. novicida U112. J Med Microbiol (2007) 0.97
Structures of OppA and PstS from Yersinia pestis indicate variability of interactions with transmembrane domains. Acta Crystallogr D Biol Crystallogr (2007) 0.96
Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis. J Infect Dis (2011) 0.96
The condition-dependent transcriptional landscape of Burkholderia pseudomallei. PLoS Genet (2013) 0.96
Genome-wide analysis reveals loci encoding anti-macrophage factors in the human pathogen Burkholderia pseudomallei K96243. PLoS One (2010) 0.94
Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis (2011) 0.94
Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence. Antimicrob Agents Chemother (2006) 0.94
Genome-wide saturation mutagenesis of Burkholderia pseudomallei K96243 predicts essential genes and novel targets for antimicrobial development. MBio (2014) 0.94
Regulated expression of the beta2-toxin gene (cpb2) in Clostridium perfringens type a isolates from horses with gastrointestinal diseases. J Clin Microbiol (2005) 0.94
O-linked glycosylation of the PilA pilin protein of Francisella tularensis: identification of the endogenous protein-targeting oligosaccharyltransferase and characterization of the native oligosaccharide. J Bacteriol (2011) 0.93
Flagellar glycosylation in Burkholderia pseudomallei and Burkholderia thailandensis. J Bacteriol (2011) 0.92
Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium. Infect Immun (2005) 0.92
Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One (2012) 0.92
DNA vaccination protects against botulinum neurotoxin type F. Vaccine (2003) 0.92
The structure of a Burkholderia pseudomallei immunophilin-inhibitor complex reveals new approaches to antimicrobial development. Biochem J (2011) 0.91